Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | FDPS | P14324 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.54 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.54 |
| ▸ | ABAT | P80404 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966450 | 0.93 | ALDH1A1 (0.70) | ALDH1A1TSHRFDPSKDM4EHTT | |
| SCHEMBL140841 | 0.89 | DRD1 (0.53) | ALDH1A1TSHRFDPSKDM4EHTT | |
| SCHEMBL29440132 | 0.89 | DRD1 (0.53) | ALDH1A1TSHRFDPSKDM4EHTT | |
| SCHEMBL1414783 | 0.87 | ALDH1A1 (0.66) | ALDH1A1TSHRFDPSKDM4EHTT | |
| SCHEMBL7538876 | 0.85 | ALDH1A1 (0.49) | ALDH1A1TSHRFDPSKDM4EHTT | |
| SCHEMBL1159006 | 0.84 | ALDH1A1 (0.72) | ALDH1A1TSHRFDPSKDM4EHTT | |
| 3,4-Dimethoxybenzaldehyde SCHEMBL29364994 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TSHRFDPSKDM4EHTT | |
| 3,4-Dimethoxybenzaldehyde SCHEMBL5308959 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TSHRFDPSKDM4EHTT | |
| 3,4-Dimethoxybenzaldehyde SCHEMBL25202 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TSHRFDPSKDM4EHTT | |
| 3,4-Dimethoxybenzaldehyde SCHEMBL1330962 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TSHRFDPSKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118546665-A | Preparation method and application of acidizing corrosion inhibitor suitable for multi-medium acid | 山东滨州昱诚化工科技有限公司 | 2024-08-27 | — | — | CN | claimed |
| US-20260124173-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250304533-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12410128-B1 | Therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250197394-A1 | ANTIBACTERIALS BASED ON MONOCYCLIC FRAGMENTS COUPLED TO AMINOPIPERIDINE NAPHTHYRIDINE SCAFFOLD | UNIVERZA V LJUBLJANI (SI) | 2025-06-19 | — | — | US | disclosed |
| WO-2025101939-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-118546665-A | Preparation method and application of acidizing corrosion inhibitor suitable for multi-medium acid | 山东滨州昱诚化工科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-117924277-A | Oxime ether compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20230270703-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | OCCURX PTY LTD (AU) | 2023-08-31 | — | — | US | disclosed |
| US-20230270703-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | OCCURX PTY LTD (AU) | 2023-08-31 | — | — | US | disclosed |
| CN-1953975-A | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-04-25 | — | — | CN | disclosed |
| EP-1697351-A1 | 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| US-20050239841-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005058883-A1 | 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| JP-2004002247-A | METHOD FOR PRODUCING 4-DIFLUOROMETHOXY-3-HYDROXYBENZALDEHYDE | DAIKIN IND LTD | 2004-01-08 | — | — | JP | disclosed |
| EP-0706513-B1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | BYK GULDEN LOMBERG CHEM FAB (DE) | 2002-05-15 | — | — | EP | disclosed |
| US-5712298-A | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-01-27 | — | — | US | disclosed |
| EP-0706513-A1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001338-A1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304533-A1 | THERAPEUTIC ALKALOID COMPOUNDS | HTR3B, MTNR1B, PNMT | ALDH1A1 2227/4885TSHR 4064/4885FDPS 2651/4885 |
| US-20260124173-A1 | THERAPEUTIC ALKALOID COMPOUNDS | ADRA1B, HTR1B, ADRB1 | ALDH1A1 903/4885TSHR 194/4885FDPS 4393/4885 |
| US-20230270703-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | ALDH1A2, RBP4, RARB | ALDH1A1 264/4885TSHR 846/4885FDPS 533/4885 |
| US-20250197394-A1 | ANTIBACTERIALS BASED ON MONOCYCLIC FRAGMENTS COUPLED TO AMINOPIPERIDINE NAPHTHYRIDINE SCAFFOLD | NPEPPS, MFN2, DNM1 | ALDH1A1 4356/4885TSHR 4808/4885FDPS 283/4885 |
| US-12410128-B1 | Therapeutic alkaloid compounds | HTR3B, MTNR1B, PNMT | ALDH1A1 2227/4885TSHR 4064/4885FDPS 2651/4885 |
| US-20050239841-A1 | New compounds | MCHR1, NPY1R, HCRTR1 | ALDH1A1 1918/4885TSHR 60/4885FDPS 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.